

# TABLE OF CONTENTS

<b>Infectious Diseases I</b> .....	1
Infectious Diseases I Panel.....	3

## New Antimicrobial Agents

*By Vellyur Viswesh, Pharm.D., BCIDP, BCCCP*

Introduction.....	7
New $\beta$ -Lactam/ $\beta$ -Lactamase Inhibitor Combinations .....	8
New Tetracycline Antimicrobials .....	14
New Aminoglycoside Antimicrobials .....	19
Clinical Approach and Formulary Considerations .....	20
References .....	23
Self-Assessment Questions.....	26

## Antimicrobial Dosing in Special Populations: CRRT and Obesity

*By Brian M. Hoff, Pharm.D., BCIDP, BCPS*

Antimicrobial Dosing in Continuous Renal Replacement Therapy .....	31
Antimicrobial Dosing in Obesity.....	35
References .....	41
Self-Assessment Questions.....	43

## Infectious Diseases II .....

Infectious Diseases II Panel .....	49
------------------------------------	----

## Multidrug-Resistant Infections

*By Lynn Wardlow, Pharm.D., MBA, MS, BCIDP; and Ashley L. Ross, Pharm.D., BCPS*

Introduction.....	53
Detection of Resistance Mechanisms .....	56
Guidelines and Resources Detailing Treatments for MDR Infections.....	58
General Approach to Managing MDR Pathogens .....	58
Managing Selected MDR Gram-positive Pathogens .....	60
Management of Selected MDR Gram-negative Pathogens .....	62
Future Studies and Promising Therapeutic Options.....	69
Antimicrobial Stewardship and Infection Prevention Strategies to Mitigate Resistance Acquisition and Transmission.....	71
Conclusion .....	72
References .....	74
Self-Assessment Questions.....	78

## CMV Infection in the Immunocompromised Patient

*By Gregory E. Malat, Pharm.D., FAST, BCPS*

Cytomegalovirus .....	83
CMV Therapy and Antivirals .....	89
Medication Strategies .....	94
CMV Antiviral Resistance .....	96
Conclusion .....	98
References .....	98
Self-Assessment Questions .....	102

## Infection in Patients Receiving Biologic Agents for Inflammatory Diseases

*By Juan E. Villanueva, Pharm.D., BCPS, BCIDP; and David E. Nix, Pharm.D., FCCP, BCPS*

Introduction.....	105
Biologic Response Modifiers .....	105
Infection Risk Assessment .....	118
Perioperative Management of Biologic Response Modifiers .....	121
COVID-19 and Biologic Response Modifiers.....	121
Conclusion .....	121
References .....	122
Self-Assessment Questions .....	126

## Infectious Diseases III .....

Infectious Diseases III Panel .....	133
-------------------------------------	-----

## Interactive Case: Penicillin Allergy

*By Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS; and Bruce M. Jones, Pharm.D., FIDSA, BCPS*

Interactive Case: Penicillin Allergy .....	137
Hyperlink to Activity.....	137
References .....	138
Self-Assessment Questions .....	139

## Interactive Case: Strategies for Antimicrobial Optimization

*By Heather D. Gibson, Pharm.D., BCIDP, BCPS*

Interactive Case: Strategies for Antimicrobial Optimization .....	143
Hyperlink to Activity.....	143
References .....	144
Self-Assessment Questions .....	146

## **Statistics in Practice: Survival Analysis and Common Applications**

*By Ryan Rodriguez, Pharm.D., BCPS; and Daniel R. Touchette, Pharm.D., MA, FCCP*

Statistics in Practice: Survival Analysis .....	151
Hyperlink to Activity.....	152
References .....	152
Self-Assessment Questions .....	153